Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use
- 13 July 2012
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 16 (7) , 1787-1798
Abstract
In sub-Saharan Africa, HIV incidence and prevalence remain disproportionately high among women. Vaginal rings (VRs) have been formulated for the delivery of antiretroviral-based microbicides, and their favorable safety and tolerability profiles reported in clinical studies. Although the concept of drug release through a VR has existed since 1970, and VRs have been marketed since 1992 for contraceptive or hormone replacement purposes, VR use as a microbicide delivery system is a novel application. This is the first study to evaluate VR adherence among African women in the context of its potential use as an HIV prevention method, to examine predictors of adherence, and to describe clinical or contextual reasons for VR removals or nonadherence. This was a randomized trial of the safety and acceptability of a placebo VR worn for 12 weeks in 170 HIV-negative, African women aged 18–35 in four clinic sites in South Africa and Tanzania. The findings suggest that adherence to VR use in the context of HIV prevention trials in these communities should be high, thereby enabling more accurate assessment of an active microbicide safety and efficacy.Keywords
This publication has 23 references indexed in Scilit:
- Unraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Advances in microbicide vaginal ringsAntiviral Research, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Safety and Pharmacokinetics of Dapivirine Delivery From Matrix and Reservoir Intravaginal Rings to HIV-Negative WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal RingAIDS Research and Human Retroviruses, 2009
- Methodological Challenges in Biomedical HIV Prevention Trials2008
- Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferencesContraception, 2007
- The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptabilityContraception, 2003
- HIV Receptors and the Pathogenesis of AIDSScience, 1996